2.30 -0.55 (-19.30%)
After hours: 7:59PM EDT
|Bid||2.30 x 1200|
|Ask||2.30 x 1200|
|Day's Range||2.81 - 2.92|
|52 Week Range||1.91 - 4.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.67|
NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Six ...
LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. Last Friday, shares in Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc. ended the session 4.35% higher at $2.40.
AVEO Oncology (AVEO) today announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective after the U.S. market closed on Friday, June 22, 2018 as part of FTSE’s annual reconstitution. “We believe that inclusion in the widely referenced Russell U.S. Indexes reflects the significant progress we have made as a Company in the last year, including European approval of tivozanib for the treatment of adult patients with advanced kidney cancer,” said Michael Bailey, president and chief executive officer of AVEO. Annual Russell U.S. Indexes reconstitution captures the 4,000 largest US stocks as of May 11, ranking them by total market capitalization.
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
AVEO Pharmaceuticals (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Jefferies 2018 Healthcare Conference in New York on Thursday, June 7, 2018 at 9:30 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need.
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want a free Stock Review on AVEO, CLDX, and CERS sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Audentes Therapeutics Inc. (NASDAQ: BOLD), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Cerus Corp. (NASDAQ: CERS).
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of F.N.B. ...
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is attracting a substantial amount of attention in the biotechnology space early morning out of Europe this week, with the company moving on and update related to one of its lead development assets in the sector. Here is a look at what happened and why it is important for AVEO and […] The post Here Is What Just Happened With Aveo Pharmaceuticals appeared first on Market Exclusive.
AVEO Oncology today reported financial results for the first quarter ended March 31, 2018 and provided a business update.
AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.
NEW YORK, NY / ACCESSWIRE / April 6, 2018 / U.S. markets ended higher on Thursday for their third straight daily gain as technology stocks recover from a series of shortcomings. The Dow Jones Industrial ...
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences:
AVEO Pharmaceuticals (AVEO) needs investors to pay close attention to the stock based on moves in the options market lately.
AVEO Oncology today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib as second-line treatment in advanced renal cell carcinoma , in the European Journal of Cancer.
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.
On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of 8 cents. The cancer drug company posted revenue of $82,000 in the period. For the year, the company reported that ...
AVEO Oncology today reported financial results for the full year ended December 31, 2017 and provided a business update.